Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 4/20 | 0.49 |
| ▸ | CYCS | P99999 | 3/20 | 0.48 |
| ▸ | TERT | O14746 | 5/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | STAT1 | P42224 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10002104 | 0.92 | TOP1 (0.53) | TOP1CYCSTERTSTAT3STAT1 | |
| SCHEMBL3912287 | 0.90 | TOP1 (0.58) | TOP1CYCSTERTSTAT3STAT1 | |
| SCHEMBL3912280 | 0.90 | TOP1 (0.58) | TOP1CYCSTERTSTAT3STAT1 | |
| SCHEMBL3913643 | 0.90 | TOP1 (0.58) | TOP1CYCSTERTSTAT3STAT1 | |
| SCHEMBL10141414 | 0.90 | TOP1 (0.58) | TOP1CYCSTERTSTAT3STAT1 | |
| SCHEMBL19326350 | 0.86 | TOP1 (0.49) | TOP1CYCSTERTSTAT3STAT1 | |
| SCHEMBL16923754 | 0.86 | TOP1 (0.46) | TOP1CYCSTERTSTAT3STAT1 | |
| SCHEMBL25704253 | 0.86 | TOP1 (0.46) | TOP1CYCSTERTSTAT3STAT1 | |
| SCHEMBL29693624 | 0.84 | TERT (0.62) | TOP1CYCSTERTABCG2ENPP2 | |
| SCHEMBL242168 | 0.84 | TERT (0.62) | TOP1CYCSTERTABCG2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11027017-B2 | PCI method for generating immune respose to antigenic molecule using checkpoint inhibitor and TLR3 ligand | PCI BIOTECH AS (NO) | 2021-06-08 | — | — | US | disclosed |
| US-10973896-B2 | Treatment or prevention of melanoma using photochemical internalization of a melanoma antigen | PCI BIOTECH AS (NO) | 2021-04-13 | — | — | US | disclosed |
| WO-2018130542-A1 | LANTHANIDE COMPLEXES COMPRISING DENDRIMERS | UNIVERSITE D'ORLEANS (FR) | 2018-07-19 | — | — | WO | disclosed |
| US-20180050105-A1 | METHOD | PCI BIOTECH AS (NO) | 2018-02-22 | — | — | US | disclosed |
| US-20170252441-A1 | COMPOUND AND METHOD | PCI BIOTECH AS (NO) | 2017-09-07 | — | — | US | disclosed |
| US-20170143811-A1 | METHOD OF TREATING MELANOMA | PCI BIOTECH AS (NO) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050105-A1 | METHOD | CD274, ICOS, CD47 | TOP1 1290/4885CYCS 4733/4885TERT 707/4885 |
| US-10973896-B2 | Treatment or prevention of melanoma using photochemical internalization of a melanoma antigen | CD47, TAP2, CD74 | TOP1 4762/4885CYCS 4150/4885TERT 2662/4885 |
| US-20170252441-A1 | COMPOUND AND METHOD | CSF3R, IL2, IL5 | TOP1 2013/4885CYCS 2836/4885TERT 3202/4885 |
| US-20170143811-A1 | METHOD OF TREATING MELANOMA | CD47, HLA-DRB1, CD74 | TOP1 4132/4885CYCS 3661/4885TERT 765/4885 |
| US-11027017-B2 | PCI method for generating immune respose to antigenic molecule using checkpoint inhibitor and TLR3 ligand | TLR3, TLR9, TLR6 | TOP1 2612/4885CYCS 4813/4885TERT 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.